HUE065344T2 - Microchip capillary electrophoresis assays and reagents - Google Patents

Microchip capillary electrophoresis assays and reagents

Info

Publication number
HUE065344T2
HUE065344T2 HUE19714055A HUE19714055A HUE065344T2 HU E065344 T2 HUE065344 T2 HU E065344T2 HU E19714055 A HUE19714055 A HU E19714055A HU E19714055 A HUE19714055 A HU E19714055A HU E065344 T2 HUE065344 T2 HU E065344T2
Authority
HU
Hungary
Prior art keywords
reagents
capillary electrophoresis
electrophoresis assays
microchip capillary
microchip
Prior art date
Application number
HUE19714055A
Other languages
Hungarian (hu)
Inventor
Timothy Riehlman
Gabriel Carreau
Jeffrey Schneiderheinze
Nicole Nall
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HUE065344T2 publication Critical patent/HUE065344T2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44743—Introducing samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44747—Composition of gel or of carrier mixture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Electrochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE19714055A 2018-03-19 2019-03-15 Microchip capillary electrophoresis assays and reagents HUE065344T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862644933P 2018-03-19 2018-03-19

Publications (1)

Publication Number Publication Date
HUE065344T2 true HUE065344T2 (en) 2024-05-28

Family

ID=65952203

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19714055A HUE065344T2 (en) 2018-03-19 2019-03-15 Microchip capillary electrophoresis assays and reagents

Country Status (21)

Country Link
US (1) US11054389B2 (en)
EP (2) EP3768709B1 (en)
JP (4) JP7315565B2 (en)
KR (3) KR102722812B1 (en)
CN (2) CN111868085B (en)
AR (1) AR117402A1 (en)
AU (2) AU2019239633B2 (en)
BR (1) BR112020015291B1 (en)
CA (2) CA3089655C (en)
DK (1) DK3768709T3 (en)
EA (1) EA202092203A1 (en)
ES (1) ES2969882T3 (en)
FI (1) FI3768709T3 (en)
HU (1) HUE065344T2 (en)
IL (2) IL277264B2 (en)
MX (2) MX2020009696A (en)
MY (1) MY202358A (en)
PL (1) PL3768709T3 (en)
SG (1) SG11202007011YA (en)
TW (2) TWI779177B (en)
WO (1) WO2019182901A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
HUE065344T2 (en) 2018-03-19 2024-05-28 Regeneron Pharma Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CN115398236B (en) * 2020-01-21 2024-06-11 瑞泽恩制药公司 Deglycosylation method for electrophoresis of glycosylated proteins
MX2023008527A (en) 2021-01-20 2023-07-28 Regeneron Pharma Methods of improving protein titer in cell culture.
CN113189184B (en) * 2021-04-28 2022-09-09 浙江大学 Capillary gel electrophoresis sample buffer containing cysteine
BR112023024984A2 (en) * 2021-06-01 2024-02-20 Regeneron Pharma AQUEOUS ELECTROPHORESIS SAMPLE BUFFER, METHOD FOR IDENTIFYING CONTAMINANTS OR IMPURITIES IN A PROTEIN DRUG SAMPLE, AND, KIT
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
TW202330104A (en) 2021-10-26 2023-08-01 美商再生元醫藥公司 Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM SUITABILITY PARAMETERS AND COLUMN AGING
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127134A (en) 1995-04-20 2000-10-03 Carnegie Mellon University Difference gel electrophoresis using matched multiple dyes
US6210915B1 (en) * 1997-12-31 2001-04-03 University Of Texas Systems Telomerase extraction method
CN100359015C (en) * 1998-05-18 2008-01-02 伦敦大学专科学院 polypeptide hormone phosphatase factor
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2445053A1 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
JP2003114216A (en) 2001-10-05 2003-04-18 Advance Co Ltd Electrophoretic device
EP1572909A4 (en) 2002-02-21 2007-06-06 Wyeth Corp A follistatin domain containing protein
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
CA2493671A1 (en) 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Lipophilic electrophoretic probes
DE10258150A1 (en) 2002-12-10 2004-07-08 Dyomics Gmbh Hydrophilic markers based on benzopyrylo-polymethines
AU2003903317A0 (en) * 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
ES2381551T3 (en) 2003-12-05 2012-05-29 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US7378396B2 (en) 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
EP1811902A2 (en) 2004-11-15 2007-08-01 (OSI) Eyetech, Inc. Marker for fenestrae
EP1801573A1 (en) 2005-12-21 2007-06-27 Boehringer Mannheim Gmbh Method and apparatus for parallel two-dimensional electrophoresis
JP5307708B2 (en) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド High affinity antibody against human IL-6 receptor
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EA022609B1 (en) 2007-02-12 2016-02-29 А1М Фарма Аб Use of free fetal haemoglobin as a marker for preeclampsia
CN101827946A (en) 2007-05-18 2010-09-08 茵维特罗根公司 Rapid protein labeling and analysis
MX2010000970A (en) 2007-07-31 2010-03-09 Regeneron Pharma Human antibodies to human cd20 and method of using thereof.
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
WO2010052556A1 (en) 2008-11-06 2010-05-14 Glenmark Pharmaceuticals S.A. Treatment with anti-alpha2 integrin antibodies
KR20100053015A (en) * 2008-11-12 2010-05-20 경희대학교 산학협력단 Naphthazarin derivative inducing apoptosis in human myeloid leukemia cell line
JO3672B1 (en) 2008-12-15 2020-08-27 Regeneron Pharma High Affinity Human Antibodies to PCSK9
WO2010078601A1 (en) 2009-01-05 2010-07-08 The Regents Of The University Of California High throughput biomolecule separation and analysis
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CN102648415A (en) 2009-08-25 2012-08-22 生命技术公司 Quantitative fluorescent protein standards
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
JOP20190250A1 (en) 2010-07-14 2017-06-16 Regeneron Pharma Stabilized formulations containing anti-ngf antibodies
AR083044A1 (en) 2010-09-27 2013-01-30 Regeneron Pharma ANTI-CD48 ANTIBODIES AND USES OF THE SAME
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3756B1 (en) 2010-11-23 2021-01-31 Regeneron Pharma Human antibodies to the glucagon receptor
AR087329A1 (en) 2011-06-17 2014-03-19 Regeneron Pharma HUMAN ANTIBODIES AGAINST PROTEIN 3 OF HUMAN ANGIOPOIETIN TYPE
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
KR102063028B1 (en) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (en) 2012-05-03 2021-01-31 Regeneron Pharma Human antibodies to FEL D1 and methods for their use
TWI641619B (en) 2012-06-25 2018-11-21 美商再生元醫藥公司 anti-EGFR antibody and use thereof
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
WO2014055936A1 (en) * 2012-10-04 2014-04-10 Integenx Inc. Preservation of biological materials in non-aqueous fluid media
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
JO3405B1 (en) 2013-01-09 2019-10-20 Regeneron Pharma ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
EP2948177A1 (en) 2013-01-22 2015-12-02 AbbVie Inc. Methods for optimizing domain stability of binding proteins
JO3532B1 (en) 2013-03-13 2020-07-05 Regeneron Pharma Anti-il-33 antibodies and uses thereof
TWI659968B (en) 2013-03-14 2019-05-21 再生元醫藥公司 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
EP2968454B1 (en) 2013-03-15 2019-02-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
TWI641620B (en) 2013-08-21 2018-11-21 再生元醫藥公司 Anti-prlr antibodies and uses thereof
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
JP6632984B2 (en) 2014-03-11 2020-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Anti-EGFRvIII antibodies and uses thereof
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
EP3636073B1 (en) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
JO3701B1 (en) 2014-05-23 2021-01-31 Regeneron Pharma Human antibiotics for MERS-CoV-coronavirus
CN107001461A (en) 2014-09-16 2017-08-01 瑞泽恩制药公司 Anti- hyperglycemic factor antibody and its application method
TWI710573B (en) 2015-01-26 2020-11-21 美商再生元醫藥公司 Human antibodies to ebola virus glycoprotein
HUE065344T2 (en) 2018-03-19 2024-05-28 Regeneron Pharma Microchip capillary electrophoresis assays and reagents

Also Published As

Publication number Publication date
FI3768709T3 (en) 2024-02-01
JP2023093664A (en) 2023-07-04
KR102503356B1 (en) 2023-02-24
EA202092203A1 (en) 2020-12-07
BR112020015291A2 (en) 2020-12-08
KR20200130821A (en) 2020-11-20
EP4317959B1 (en) 2026-04-29
JP7486637B2 (en) 2024-05-17
IL277264B1 (en) 2023-11-01
KR102777672B1 (en) 2025-03-10
TWI779177B (en) 2022-10-01
DK3768709T3 (en) 2024-01-29
AU2026201984A1 (en) 2026-04-02
KR20240157124A (en) 2024-10-31
IL277264B2 (en) 2024-03-01
CN111868085A (en) 2020-10-30
TW202516175A (en) 2025-04-16
US20190285580A1 (en) 2019-09-19
TW202323813A (en) 2023-06-16
CA3246952A1 (en) 2025-10-31
JP2025156526A (en) 2025-10-14
CN119335032A (en) 2025-01-21
ES2969882T3 (en) 2024-05-23
IL277264A (en) 2020-10-29
CA3089655C (en) 2026-01-20
MY202358A (en) 2024-04-24
JP7724903B2 (en) 2025-08-18
TW202004178A (en) 2020-01-16
SG11202007011YA (en) 2020-08-28
KR102722812B1 (en) 2024-10-29
AU2019239633A1 (en) 2020-11-19
TWI854343B (en) 2024-09-01
WO2019182901A1 (en) 2019-09-26
CA3089655A1 (en) 2019-09-26
JP7315565B2 (en) 2023-07-26
EP3768709A1 (en) 2021-01-27
IL307577B1 (en) 2025-02-01
AU2019239633B2 (en) 2025-12-18
AR117402A1 (en) 2021-08-04
EP4317959A3 (en) 2024-03-27
MX2020009696A (en) 2020-10-07
IL307577B2 (en) 2025-06-01
KR20230031987A (en) 2023-03-07
IL307577A (en) 2023-12-01
CN111868085B (en) 2024-11-05
BR112020015291B1 (en) 2023-09-26
US11054389B2 (en) 2021-07-06
JP2021516334A (en) 2021-07-01
EP3768709B1 (en) 2023-12-27
JP2024097873A (en) 2024-07-19
PL3768709T3 (en) 2024-05-20
EP4317959A2 (en) 2024-02-07
MX2024012221A (en) 2024-11-08

Similar Documents

Publication Publication Date Title
IL277264A (en) Microchip capillary electrophoresis assays and reagents
HUE059673T2 (en) Nucleic acid sequencing using affinity reagents
EP3698872A4 (en) MICROFLUIDIC DETECTION CHIP FOR MULTI-CHANNEL FAST DETECTION
GB2578528B (en) Mixed-phase fluids for nucleic acid sequencing and other analytical assays
EP3885760A4 (en) MICROFLUIDIC CHIP
IL301855B2 (en) Reagents and methods for the analysis of linked nucleic acids
IL269779A (en) Methods and reagents for the analysis of protein-protein interfaces
IL290274A (en) Methods and reagents for nucleic acid sequencing and related applications
EP3717916C0 (en) TARGET-INTERFERENCE-SUPRESSED ANTI-DRUG ANTIBODY ASSAY
EP3779435A4 (en) Microfluidic chip and analytical instrument provided with microfluidic chip
HUE048752T2 (en) Sample receiving element, assay kit and method for analyzing a liquid, in particular a coolant-emulsion
EP3464598A4 (en) APTAMER-BASED ANALYTE ASSAYS
EP3932552C0 (en) MICROFLUIDIC CHIP
EP4159872C0 (en) DNA MARKING
EP3634635C0 (en) SAMPLE AND REAGENT CONTAINERS WITH ANTI-VACUUM FUNCTION
DK3484623T3 (en) DISPENSER FOR LIQUID ANALYTICAL REAGENTS AND ANALYTICAL KITS AND RELATED PROCEDURES
EP3264085A4 (en) Immunoassay method and assay reagent used in said method
SG11202102265UA (en) Hemoglobin assay reagent, assay kit and assay method
SG11202109518PA (en) Disposition of reagents in assay device
IL271237A (en) Image capillary isoelectric focusing for the analysis of protein variants in a sample matrix
IL281796A (en) Antibody quantification in biological samples
IL282384A (en) Antibodies specific for glycosylated apoj and uses thereof
GB2579810B (en) Assay Analysis
EP3663410A4 (en) NUCLEIC ACID DETECTION METHOD AND REAGENT REAGENT
IL308864A (en) Microchip capillary electrophoresis assays and reagents